Topic: Noven Pharmaceuticals Inc.
Posted on 10/14/11 at 8:30am by Eddie Staley . Watson Pharmaceuticals, Inc. (NYSE: WPI ) today confirmed that its subsidiary, Watson Laboratories...
Attention Deficit Hyperactivity Disorder (ADHD) inability or condition which prevents a person from being able to focus and concentrate on task or a purpose. Subsequently, in December 2005 the Psychopharmacologic Drug Advisory Committee recommended to the US FDA that DAYTRANA is safe ...
First and Only Patch for ADHD Now to be Marketed and Sold by Noven Therapeutics. Jeffrey Eisenberg, Noven's President and Chief Executive Officer, said: "We are very pleased to complete the acquisition and to add Daytrana ' a product developed and manufactured ...
The article reports that Noven Pharmaceuticals of Miami, Florida has completed the previously announced acquisition of specialty pharmaceutical company JDS Pharmaceuticals of New York for $125 million. The acquisition provides Noven with a psychiatry pipeline that includes one pending new drug application ...
NOVN) today announced positive top-line results from its Phase 2 clinical study evaluating MesafemT (low-dose paroxetine mesylate) for the treatment of vasomotor symptoms (hot flashes) associated with menopause (" These forward-looking statements are based largely on the current expectations of Noven and are ...
Noven Pharmaceuticals, Inc. (NOVN) Q3 2008 Earnings Call Transcript November 06, 2008 11:00 am ET. On the line to discuss our results and answer your questions are Peter Brandt, Noven's President and CEO; Mike Price, our Chief Financial Officer and ...
Noven Pharmaceuticals, Inc. (NOVN) Q2 2008 Earnings Call Transcript August 06, 2008 11:00 am ET. On the line to discuss our results and answer your questions are Peter Brandt, Noven's President and CEO; Michael Price, our Chief Financial Officer; and ...
NOVN) today provided an update on the status of Daytrana(R), the only transdermal patch indicated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).. Daytrana(R), developed and manufactured by Noven, is licensed globally to Shire Limited. Shire ...
NOVN) today announced that the U.S. Food and Drug Administration (FDA) has issued a tentative approval letter related to the New Drug Application (NDA) for Stavzor (valproic acid delayed release capsules) in 125mg, 250mg and 500mg strengths. Noven acquired a license ...
FDA Issues Approvable Letter for Stavzor Delayed Release Valproic Acid Capsules Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter related to the New Drug Application (NDA) for Stavzor (delayed release valproic ...
